Catalyst Wire Dossier Catalyst Wire Dossier

Cyramza (ramucirumab)

ramucirumab · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Cyramza (ramucirumab), covering 2026-03-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma [Phase 2]

See pricing